RCT | Switch to fulvestrant and palbociclib in breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy.
7 Oct, 2022 | 14:12h | UTCSwitch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial – The Lancet Oncology (free for a limited period)